Dorado P - Search Results

1

Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.

Almoguera B, Riveiro-Alvarez R, Gomez-Dominguez B, Lopez-Rodriguez R, Dorado P, Vaquero-Lorenzo C, Dal-Ré R, Fernandez-Piqueras J, Llerena A, Abad-Santos F, Ayuso C. Almoguera B, et al. Among authors: dorado p. Pharmacogenomics. 2010 Nov;11(11):1619-25. doi: 10.2217/pgs.10.131. Pharmacogenomics. 2010. PMID: 21121779

2

Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.

LLerena A, Berecz R, Dorado P, de la Garza CS, Norberto MJ, Cáceres M, Gutiérrez JR. LLerena A, et al. Among authors: dorado p. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):213-9. doi: 10.1016/s1570-0232(02)00661-x. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12450541

3

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.

LLerena A, Berecz R, de la Rubia A, Dorado P. LLerena A, et al. Among authors: dorado p. J Psychopharmacol. 2002 Dec;16(4):361-4. doi: 10.1177/026988110201600411. J Psychopharmacol. 2002. PMID: 12503836 Clinical Trial.

4

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.

Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A. Berecz R, et al. Among authors: dorado p. Eur J Clin Pharmacol. 2003 May;59(1):45-50. doi: 10.1007/s00228-003-0576-4. Epub 2003 Mar 28. Eur J Clin Pharmacol. 2003. PMID: 12682803 Clinical Trial.

5

CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. Dorado P, et al. Eur J Clin Pharmacol. 2003 Jul;59(3):221-5. doi: 10.1007/s00228-003-0588-0. Epub 2003 May 7. Eur J Clin Pharmacol. 2003. PMID: 12734606 Clinical Trial.

6

Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios.

Dorado P, Berecz R, Cáceres MC, LLerena A. Dorado P, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jun 15;789(2):437-42. doi: 10.1016/s1570-0232(03)00137-5. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12742136

7

Reproducibility over time of the urinary diclofenac/4'-OH diclofenac ratio among different CYP2C9 genotypes.

Dorado P, Berecz R, Cáceres MC, Conzález I, Llerena A. Dorado P, et al. Eur J Drug Metab Pharmacokinet. 2003 Jul-Sep;28(3):213-5. doi: 10.1007/BF03190487. Eur J Drug Metab Pharmacokinet. 2003. PMID: 14527094

8

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM. LLerena A, et al. Among authors: dorado p. Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. doi: 10.1007/s00228-003-0707-y. Epub 2004 Jan 16. Eur J Clin Pharmacol. 2004. PMID: 14726986 Clinical Trial.

9

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.

LLerena A, de la Rubia A, Berecz R, Dorado P. LLerena A, et al. Among authors: dorado p. Pharmacopsychiatry. 2004 Mar;37(2):69-73. doi: 10.1055/s-2004-815528. Pharmacopsychiatry. 2004. PMID: 15048614

10

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

Llerena A, Berecz R, Dorado P, de la Rubia A. Llerena A, et al. Among authors: dorado p. J Psychopharmacol. 2004 Jun;18(2):189-93. doi: 10.1177/0269881104042618. J Psychopharmacol. 2004. PMID: 15260906

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters